Floatz logo

Taselisib

Progesterone Receptor Negative

Vanderbilt-Ingram Cancer CenterSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Progesterone Receptor Negative cohort.

Asset / SponsorPhaseRating
Carboplatin
Northwestern University
Phase 3BBB
Epirubicin
Massachusetts General Hospital
Phase 2BB
Pembrolizumab
Massachusetts General Hospital
Phase 2BB
Cyclophosphamide
Massachusetts General Hospital
Phase 3BB
Capecitabine
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Taselisib is also rated in:

breast carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →
lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →